GH replacement has been offered to childhood cancer and intracranial tumour survivors in remission from primary disease for many years and has been deemed safe, as outlined in two Endocrine Society practice guidelines (6, 7). This evidence concerns the gene GH1 and childhood malignant neoplasm.